Literature DB >> 33506051

In-Hospital Peak Glycemia in Predicting No-Reflow Phenomenon in Diabetic Patients with STEMI Treated with Primary Percutaneous Coronary Intervention.

Fang Liu1, Rui Huang1, Ya Li1, Surui Zhao1, Yue Gong1, Zesheng Xu1.   

Abstract

Although percutaneous coronary intervention (PCI) significantly improves the prognosis for myocardial infarction, the no-reflow phenomenon is still the major adverse complication of PCI leading to increased mortality, especially for the patients with ST-segment elevation myocardial infarction (STEMI) combined with diabetes. To reduce the occurrence of no-reflow, prognostic factors must be identified for no-reflow phenomenon before PCI. A total of 262 participants with acute STEMI and diabetes were recruited into our cardiovascular center and underwent primary PCI for the analyses of prognostic factors of no-reflow. The patients were divided into two groups according to thrombolysis in myocardial infarction (TIMI): the normal flow and no-reflow groups, and related factors were analyzed with different statistical methods. In the present investigation, the in-hospital peak glycemia was significantly higher in the no-reflow group than the normal flow group, while more narrowed vessels, higher level of initial TIMI flow, were observed in the patients of the no-reflow group. A multivariate logistic regression analysis further demonstrated that peak glycemia was an independent predictor for no-reflow in the diabetic patients with STEMI. Our data indicated the importance of the proper control of glucose before PCI for the diabetic patients with STEMI before PCI to reduce the occurrence of the no-reflow after operation.
Copyright © 2021 Fang Liu et al.

Entities:  

Year:  2021        PMID: 33506051      PMCID: PMC7811415          DOI: 10.1155/2021/6683937

Source DB:  PubMed          Journal:  J Diabetes Res            Impact factor:   4.011


  40 in total

1.  Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction.

Authors:  G A Oswald; C C Smith; D J Betteridge; J S Yudkin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

2.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

3.  Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.

Authors:  R Marfella; K Esposito; R Giunta; G Coppola; L De Angelis; B Farzati; G Paolisso; D Giugliano
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

Review 4.  Myocardial no-reflow in humans.

Authors:  Giampaolo Niccoli; Francesco Burzotta; Leonarda Galiuto; Filippo Crea
Journal:  J Am Coll Cardiol       Date:  2009-07-21       Impact factor: 24.094

5.  Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.

Authors:  Katsuomi Iwakura; Hiroshi Ito; Masashi Ikushima; Shigeo Kawano; Atsushi Okamura; Katsuaki Asano; Tadashi Kuroda; Koji Tanaka; Tohru Masuyama; Masatsugu Hori; Kenshi Fujii
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

6.  Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy--a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil.

Authors:  Hitoshi Matsuo; Sachiro Watanabe; Takatomo Watanabe; Shunichiro Warita; Tai Kojima; Takeshi Hirose; Makoto Iwama; Koji Ono; Haruki Takahashi; Tomonori Segawa; Shinya Minatoguchi; Hisayoshi Fujiwara
Journal:  Am Heart J       Date:  2007-09-14       Impact factor: 4.749

7.  Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation.

Authors:  L Galiuto; A Lombardo; A Maseri; L Santoro; I Porto; D Cianflone; A G Rebuzzi; F Crea
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

8.  Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention.

Authors:  Braim M Rahel; Frank L J Visseren; Maarten-Jan Suttorp; Thijs H W Plokker; Johannes C Kelder; Bartelt M de Jongh; K Paul Bouter; Rob J A Diepersloot
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

9.  Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention.

Authors:  Jun-Nan Wang; You-You Yan; Zi-Yuan Guo; Ya-Juan Jiang; Lu-Lu Liu; Bin Liu
Journal:  Chin Med J (Engl)       Date:  2016-12-05       Impact factor: 2.628

10.  Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.

Authors:  Claes Held; Harvey D White; Ralph A H Stewart; Andrzej Budaj; Christopher P Cannon; Judith S Hochman; Wolfgang Koenig; Agneta Siegbahn; Philippe Gabriel Steg; Joseph Soffer; W Douglas Weaver; Ollie Östlund; Lars Wallentin
Journal:  J Am Heart Assoc       Date:  2017-10-24       Impact factor: 5.501

View more
  2 in total

Review 1.  Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data.

Authors:  Annunziata Nusca; Francesco Piccirillo; Federico Bernardini; Aurelio De Filippis; Federica Coletti; Fabio Mangiacapra; Elisabetta Ricottini; Rosetta Melfi; Paolo Gallo; Valeria Cammalleri; Nicola Napoli; Gian Paolo Ussia; Francesco Grigioni
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

2.  Effect of Admission Hyperglycemia on Short-Term Prognosis of Patients with Non-ST Elevation Acute Coronary Syndrome without Diabetes Mellitus.

Authors:  Wei Liu; Zhijuan Li; Shiying Xing; Yanwei Xu
Journal:  J Diabetes Res       Date:  2021-12-06       Impact factor: 4.011

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.